Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average […]
Truist Financial restated their buy rating on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. Several other research firms also recently commented on AMRX. StockNews.com started coverage on Amneal Pharmaceuticals in a report on […]